Read the atlas acs 2 timi 51 trial and the burden of missing data, journal of the american college of cardiology on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Anticoagulation and antiplatelet therapy in acute coronary. Phase iiiphase iii the pivotal atlas acs 2timi 51 study. Methods the atlas acs 2 timi 51 study was a placebocontrolled trial that randomly assigned 15,526 patients with recent acs to receive twicedaily doses of either 2. Management of rivaroxaban in relation to bodyweight and. Atlas acs 2timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome. Polish registry of acute coronary syndromes pl acs. The association between baseline wbc count and a composite of thrombolysis in myocardial infarction timi major. Results of the highly anticipated atlasacs 2 timi 51 demonstrate that acs patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. The page includes a summary of phase iii clinical trials, an overview of indications under investigation by the different drugs and helpful services for patients and healthcare professionals.
Appraise 2 the second apixaban for prevention of acute ischemic events trial50 atlas acs 2 timi 51 the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 trial49 atollthe acute stemi treated with primary pci and intravenous. The company said the drug was associated with a statistically significant reduction in the primary composite end. For full access to this pdf, sign in to an existing account, or purchase an annual subscription. Request pdf relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome from the atlas acs 2 timi 51 trial an elevated white blood cell wbc. Rivaroxaban in patients stabilized after a stsegment. A major subanalysis of the atlas acs 2timi 51 study in 7,817 acs patients with a recent stemi demonstrated that xarelto 2. Methods study population the study included patients. Rivaroxaban in patients stabilized after a stsegment elevation myocardial infarction. The atlas acs 2timi 51 trial and the burden of missing. Investigators in the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction 51 atlas acs 2. Atlas acs 2 timi 51 was arandomized, double blinded, placebo controlled trial that enrolled 15,526 subjects with an acs to either placebo or rivaroxaban. The present analysis is restricted to those pts who continued their background dual antiplatelet therapies during the trial, thus avoiding dilution by pts who did not receive such therapies and providing a rigorous test of the additive role of rivaroxaban. The present analysis is restricted to those pts who continued their background dual antiplatelet therapies during the trial, thus avoiding dilution by pts who did not receive such therapies and.
The antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. Despite the current standard of prolonged dual antiplatelet therapy with aspirin and a p2y 12 receptor antagonist for patients after an acs, risk for recurrent ischemic cv events remains high. Atlas acs2, timi 51 2012 randomized 15,342 patients with recent acs to either twicedaily doses of either 2. The pivotal atlas acs 2 timi 51 study proves xarelto 2. The effect of rivaroxaban on myocardial infarction in the. Efficacy and safety data for the first 2 years came from the atlas acs 2 timi 51 trial. In atlas acs 2 timi 51, rivaroxaban reduced cv events in patients pts with a recent acs. Characteristics, treatments and outcomes of patients with acute coronary. The effect of rivaroxaban on myocardial infarction in the atlas acs 2 timi 51 trial. Longterm probabilities were extrapolated using safety and effectiveness of acetylsalicylic acid data, which was estimated from published literature, assuming constant rates in time. Rivaroxaban is the only novel oral anticoagulant oac that has finalised a phase iii clinical trial in acute coronary syndrome acs with a. Rivaroxaban with or without aspirin in stable cardiovascular disease.
Timi 51 to evaluate the strategy of combining rivaroxaban with aspirin compared with treatment with aspirin alone in the. Fulltext article available only as a pdf file for download. An efficacy and safety study for rivaroxaban in patients. Relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome from the atlas acs 2 timi 51 trial. In this issue of the journal of the american heart association jaha, gibson and colleagues 10 report a secondary analysis of the efficacy and safety of rivaroxaban 2. Efficacy and safety data are consistent with results of the. Findings from the atlas acs 2 timi 51 trial, journal of the american college of cardiology on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Rivaroxaban in patients with a recent acute coronary syndrome. Events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2 timi 51 study randomized 15,526 patients with a recent acs to rivaroxaban 2. Atlas timi 51 jungwon suh seoul national university, korea potent platelet inhibition is a cornerstone in the management of acute coronary syndrome acs. Gibson cm1, chakrabarti ak, mega j, bode c, bassand jp, verheugt fw, bhatt dl, goto s, cohen m, mohanavelu s, burton p, stone g, braunwald e. The atlas acs 2timi 51 study multivu, a cision company. Lowdose rivaroxaban reduced mortality in patients with a.
On the basis of the graded increase in bleeding across doses of rivaroxaban in both strata 1 and 2 in conjunction with the efficacy noted at lower doses of the factor xa inhibitor, 2 5 mg and 5 mg of rivaroxaban administered twice daily have been selected for further assessment in a large, phase iii clinical trial atlas acs 2 timi 51. Relation of white blood cell count to bleeding and. Rivaroxaban reduced mortality post acute coronary syndrome atlas acs 2 timi 51. Comparison of two potent antithrombotic regimens in acs. Ticagrelor has demonstrated survival benefits for patients with acs and has been recommended as a drug of choice in the current practice guidelines. Reduction of stent thrombosis in patients with acute. A subset of patients had their wbc count measured at baseline. Investigators in the antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 atlas acs 2. An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome. The atlas acs 2 timi 51 trial found rivaroxaban reduced the risk for the composite endpoint of death from cardiovascular causes, mi or stroke vs. In the atlas acs 2 timi 51 trial, 2,402 patients 15.
Recent acute coronary syndrome the atlas acs 2 timi 51 trial the second trial of a ntixa t herapy to l ower cardiovascular events in a ddition to standard therapy in s ubjects with. The atlas acs 2 timi 51 trial was conducted to evaluate rivaroxaban together with standard antiplatelet therapy asa alone or asa with clopidogrel or ticlopidine versus standard antiplatelet therapy alone, for the prevention of atherothrombotic events in adult patients with elevated cardiac biomarkers after an acs mega et al. Acute coronary syndrome acs is a serious and life threatening condition. Bayer has announced that the oral anticoagulant, rivaroxaban, has reduced ischaemic events but increased bleeding in acute coronary syndrome acs patients in the largescale trial atlas acs 2 timi 51. This website is a free of charge service from daiichi sankyo europe gmbh. According to first author on the study, dr jessica mega brigham and womens hospital, boston, ma, the phase 3 trial, dubbed atlas acs 2 timi 51, is already up and running with a target. Rivaroxaban reduces events in atlasacs the british. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in atlas acs 2 timi 51. Whether that risk can be safely reduced by adding an anticoagulant to post acs therapy was addressed in the atlas acs 2 timi 51 trial, which found that rivaroxaban was associated with a reduction in. Atlas acs 2 timi 51 antixa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndromethrombolysis in myocardial infarction 51 is the largest study to date to test a novel xa inhibitor, rivaroxaban, in patients with an acute coronary syndrome acs. Rivaroxabanrivaroxaban in subjects with acute coronary syndrome in subjects with acute coronary syndrome c.
319 133 281 885 1526 1206 461 800 260 947 1134 203 1034 976 1268 1150 417 968 218 712 1367 315 771 419 125 884 566 294